近日，
通过筛选美国食品和药物管理局（FDA）批准的药物库，课题组研究人员确定了芬烯酮，一种肾脏疾病药物，作为一种有希望恢复POI生育能力的药物。芬芬烯酮刺激老年小鼠卵泡发育，并在口服给药后恢复POI患者的窦卵泡发育，导致成熟的卵母细胞和胚胎。从机制上讲，细烯酮减少了卵巢间质中的纤维化沉积，减轻了胶原介导的卵泡发育抑制。基于这一见解，课题组确定了FDA批准的其他口服抗纤维化药物作为POI相关不孕症的潜在治疗方法。他们的发现强调了卵巢基质——而不是卵泡本身——是关键的治疗靶点，并为POI相关不孕提供了潜在的治疗线索。
据悉，目前，由于患者缺乏激素反应性的窦腔卵泡，尚无有效的治疗方法治疗与卵巢早衰（POI）相关的不孕症。
附：英文原文
Title: Antifibrotic drug finerenone restores fertility in premature ovarian insufficiency
Author: Zexiong Lin, Yuan Li, Yu Zhao, Dongteng Liu, Shuzi Deng, Jingkai Gu, Yanyan Li, Xudong Zhao, Peishan Wu, Yuan Xiao, Jiaping Su, Yiting Sun, Yihui Zhang, Yin Lau Lee, Yorino Sato, Haitao Zeng, Haonan Lu, Juanhui Zhang, Jennifer K.Y. Ko, Jing Zhao, Kazuhiro Kawamura, Ernest H.Y. Ng, Shanfang Jiang, Yu Li, Xi Xia, Karen K.L. Chan, William S.B. Yeung, Tianren R. Wang, Kui Liu
Issue&Volume: 2026-02-05
Abstract: Currently, no effective treatment exists for infertility associated with premature ovarian insufficiency (POI) because affected patients lack hormone-responsive antral follicles. By screening a Food and Drug Administration (FDA)–approved drug library, we identified finerenone, a kidney disease medication, as a promising drug for restoring fertility in POI. Finerenone stimulated follicle development in aged mice and restored antral follicle development in patients with POI following oral administration, resulting in mature oocytes and embryos. Mechanistically, finerenone reduced fibrotic deposition in the ovarian stroma, alleviating collagen-mediated suppression of follicular development. Building on this insight, we identified additional FDA-approved oral antifibrotic drugs as potential treatments for POI-related infertility. Our findings highlight the ovarian stroma—rather than the follicles themselves—as the key therapeutic target and offer potential therapeutic leads for POI-related infertility.
DOI: adz4075
Source: https://www.science.org/doi/10.1126/science.adz4075